CDK4/6 inhibitors in early stage HR+/HER2- disease

CDK4/6 Inhibitors Breast Cancer Nemeses is the EBC Party Over for Real-World Dance-Off?Подробнее

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 InhibitionПодробнее

Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...Подробнее

Individualizing the Selection of First-Line Therapy for Patients with HR-Positive Metastatic BCПодробнее

Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Canc...Подробнее

FDA Approves Ribociclib (Kisqali) for Stage 2-3 HR+/HER2- Breast Cancer at Higher Risk of RecurrenceПодробнее

Impact of CDK4/6 inhibitors on HR-positive, HER2-negative advanced breast cancerПодробнее

FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer ESMO 2024Подробнее

Community Collaboration: Application of CDK 4/6 Inhibitors in the Treatment of HR-Positive/HER2-N...Подробнее

Current state of CDK4/6 inhibitors in metastatic HER2-negative breast cancerПодробнее

New Advances and Opportunities for Improvement in HR+/HER2- Early Breast CancerПодробнее

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast CancerПодробнее

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancerПодробнее

Important considerations in the management of HR+, HER2-negative early breast cancerПодробнее

Treatment benefit of CDK4/6 inhibitors in HR+/HER2- aBC in clinical trials and the real worldПодробнее

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancerПодробнее

2022 KU Post San Antonio Review | Early-Stage Hormone + Breast Cancer: Optimizing Systemic TherapyПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее